Ireland Sees Rising Shingles Vaccination Demand Driven by Dementia Risk Studies
An increasing number of adults in Ireland are paying privately for the shingles vaccine, not just to prevent the painful skin condition, but in an effort to ward off dementia, according to the article. Driven by recent observational studies from Stanford and Oxford universities linking the inoculation to reduced cognitive decline rates, patients such as 60-year-olds with strong family histories of the illness are bypassing the state schedule to secure the two-dose Shingrix series.
Professor Seán Kennelly on Neuroprotective Vaccine Evidence
Professor Seán Kennelly, a consultant in geriatric medicine and director of the Institute of Memory and Cognition at Tallaght University Hospital, explained that his department advises getting the inoculation because research points to a distinct connection between receiving the jab and favorable results in lowering dementia vulnerability. While the vaccine is already recognized as highly effective at preventing shingles in adults over 50, Kennelly noted that it appears to carry additional neuroprotective benefits. Precisely how the protection works remains unproven, though researchers theorize that suppressing the varicella-zoster virus (VZV) lowers systemic inflammation that can thicken blood and cause brain microvascular changes, or that the vaccine’s immune-enhancing adjuvant helps modulate the brain’s defenses.
Stanford and Oxford University Studies Shape the Debate
The hypothesis gained momentum following natural experiments and large-scale health record reviews. When Wales launched a shingles vaccination rollout in 2013 using the older Zostavax shot, it imposed a strict birthdate cutoff for eligibility, which scientists from Stanford University used to compare dementia diagnoses across otherwise identical populations. The Stanford team found that vaccination lowered the seven-year probability of a new dementia diagnosis by 3.5 percent, a relative decrease of 20 percent that was especially pronounced in women. A subsequent 2024 Oxford University study tracking more than 200,000 vaccinated patients found that rates were 17 percent lower over six years among those given the newer Shingrix vaccine compared to Zostavax.
Susan O’Dwyer and Dr Patrick Kelly on Cautious Medical Stance
Despite the promising data, medical bodies urge caution against viewing the vaccine as a proven cognitive shield. Susan O’Dwyer, head of professional services at the Irish Pharmacy Union, emphasized that current studies show correlation rather than direct causation. “We have not yet determined if it’s the vaccine itself that directly reduces dementia risk,” O’Dwyer stated, adding that pharmacists currently do not recommend the injection strictly for dementia prevention. Dr Patrick Kelly, a general practitioner and the Irish College of GPs’ clinical lead for primary care immunisation, concurred that conclusive evidence is absent, citing a May review by the Health Information and Quality Authority (Hiqa) which determined that additional study is necessary.
Government Program to Replace Private Shingles Vaccine Costs
Currently, patients must request Shingrix privately through GP surgeries or local pharmacies, paying up to €490 for the two required doses. That financial barrier is set to change under the Irish Government’s Budget 2027 announcements, which include a phased national shingles immunization program scheduled to start in June next year. The rollout will begin with immunocompromised individuals over 65 before expanding to the wider older adult cohort. Professor Kennelly noted that state-funded access will ease the financial strain on older patients while potentially generating major cost savings for the health service if broader dementia rates decline.
Research Trials to Advance Dementia Prevention Methods
Definitive answers may arrive by April 2030, when clinical trials currently underway in Denmark and Finland are scheduled to release initial data. In the interim, public health organizations emphasize established lifestyle interventions to manage cognitive decline. These steps include managing blood pressure, treating diabetes, exercising regularly, and prioritizing sleep. With research by Alzheimer’s Europe calculating that the number of dementia cases in Ireland would more than double to 151,092 by 2050 based on an ageing population, researchers continue to investigate every viable avenue to protect brain health.
Related reading